



# ANUH PHARMA LTD.

**Registered Office** : 3-A, Shivsagar Estate, North Wing,  
Dr. Annie Besant Road, Worli, **MUMBAI** - 400 018. **INDIA**.  
**Tel.** : +91-22-6622 7575 • **Fax** : +91-22-6622 7600 / 7500  
**E-Mail** : anuh@sk1932.com • **CIN**: L24230MH1960PLC011586

Date: 7<sup>th</sup> November, 2022

To,  
The Manager (Listing)  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort, Mumbai - 400 001

**Ref: Scrip Code No. 506260**

**Sub: Outcome of Board Meeting dated 7<sup>th</sup> November, 2022.**

Dear Sir/Madam,

Pursuant to the provisions of Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, this is to inform you that the Board of Directors of the Company (the "Board") at its Meeting held today i.e. Monday, 7<sup>th</sup> November, 2022, inter-alia considered and approved the following agenda Items:

1. The Un-audited Financial Results along with Limited Review Report thereon for the quarter ended 30<sup>th</sup> September, 2022.

The Meeting of the Board of Directors commenced at 12:30 PM and concluded at 3:15 PM.

Thanking you,

Yours faithfully,  
For **Anuh Pharma Ltd.**

**Bharat Gangani**  
**Company Secretary & Compliance Officer**



**Encl: Un-audited Financial Results along with Limited Review Report**



**We Serve Since 1932**

**Factory** : E-17/3, E-17/4 & E-18, M.I.D.C., Tarapur, BOISAR, Dist. Paighar - 401 506, INDIA. **Tel.:** +91-7410055574 / 75

**Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

**TO THE BOARD OF DIRECTORS**  
**Anuh Pharma Limited**

1. We have reviewed the accompanying statement of unaudited financial results of Anuh Pharma Limited (the "Company") for the quarter and half year ended 30th September, 2022 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.



**For JAYANTILAL THAKKAR & CO.**  
**CHARTERED ACCOUNTANTS**  
**(FIRM REG. NO. 104133W)**

*D. J. Thakkar*

**DILIP J. THAKKAR**  
**PARTNER**  
**MEMBERSHIP NO. 005369**  
**UDIN: 22005369BCJEQ54740**

**PLACE: Mumbai**  
**DATE: 7<sup>th</sup> November, 2022**

## ANUH PHARMA LTD.

CIN: L24230MH1960PLC011586

Regd. Office : 3-A, North Wing, Shivsagar Estate, Dr. Annie Besant Road, Worli, Mumbai - 400018

Tel: +91 22 6622 7575; Fax: +91 22 6622 7600; Email: anuh@sk1932.com; Website: www.anuhpharma.com

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30th SEPTEMBER, 2022

(Rs. in Lakhs)

Sr. No.	Particulars	3 months ended	3 months ended	3 months ended	6 months ended	6 months ended	12 months ended
		30/09/2022	30/06/2022	30/09/2021	30/09/2022	30/09/2021	31/03/2022
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)
I.	Revenue from operations	11,506.98	11,637.65	10,874.04	23,144.63	22,601.21	48,664.62
II.	Other income	200.97	95.50	190.51	296.47	382.96	519.71
III.	<b>Total Income (I + II)</b>	<b>11,707.95</b>	<b>11,733.15</b>	<b>11,064.55</b>	<b>23,441.10</b>	<b>22,984.17</b>	<b>49,184.33</b>
IV.	Expenses:						
	Cost of materials consumed	7,574.24	8,738.05	7,829.79	16,312.29	16,845.36	35,171.18
	Purchases of Stock-in-Trade	159.26	701.97	7.06	861.23	409.58	3,082.53
	Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	662.64	(607.58)	392.67	55.06	460.98	(485.63)
	Employee benefits expense	421.80	425.92	363.14	847.72	732.65	1,510.05
	Finance costs	10.61	5.98	38.51	16.59	56.10	96.09
	Depreciation and amortization expense	244.19	241.75	296.96	485.94	596.10	1,195.97
	Other expenses	1,346.30	1,260.83	1,033.11	2,607.13	2,068.66	4,701.94
	<b>Total expenses (IV)</b>	<b>10,419.04</b>	<b>10,766.92</b>	<b>9,961.24</b>	<b>21,185.96</b>	<b>21,169.43</b>	<b>45,272.13</b>
V.	<b>Profit / (Loss) before exceptional and items and tax (III - IV)</b>	<b>1,288.91</b>	<b>966.23</b>	<b>1,103.31</b>	<b>2,255.14</b>	<b>1,814.74</b>	<b>3,912.20</b>
VI.	Exceptional items	-	-	-	-	-	-
VII.	<b>Profit / (Loss) before tax (V - VI)</b>	<b>1,288.91</b>	<b>966.23</b>	<b>1,103.31</b>	<b>2,255.14</b>	<b>1,814.74</b>	<b>3,912.20</b>
VIII.	Tax expenses:						
	(1) Current tax	309.00	246.00	267.00	555.00	441.00	1,058.00
	(2) Deferred tax	(11.61)	(13.30)	(23.43)	(24.91)	(45.03)	(99.46)
	(3) Income tax of earlier years	-	-	-	-	-	(102.47)
	<b>Total Tax expenses (VIII)</b>	<b>297.39</b>	<b>232.70</b>	<b>243.57</b>	<b>530.09</b>	<b>395.97</b>	<b>856.07</b>
IX.	<b>Profit/(Loss) after Tax (VII-VIII)</b>	<b>991.52</b>	<b>733.53</b>	<b>859.74</b>	<b>1,725.05</b>	<b>1,418.77</b>	<b>3,056.13</b>
X.	Other Comprehensive Income (net of Tax)						
	(i) Items that will not be reclassified to profit or loss	(9.02)	1.70	4.38	(7.32)	0.89	8.48
	(ii) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	<b>Total Other Comprehensive Income (net of Tax) (X)</b>	<b>(9.02)</b>	<b>1.70</b>	<b>4.38</b>	<b>(7.32)</b>	<b>0.89</b>	<b>8.48</b>
XI.	<b>Total Comprehensive Income for the period (IX + X) (Comprising Profit / (Loss) and Other Comprehensive Income for the period)</b>	<b>982.50</b>	<b>735.23</b>	<b>864.12</b>	<b>1,717.73</b>	<b>1,419.66</b>	<b>3,064.61</b>
	Paid up Equity Share Capital (Face value ₹ 5/- each)	2,505.60	2,505.60	2,505.60	2,505.60	2,505.60	2,505.60
	Other Equity (excluding revaluation reserves)						18,871.68
XII.	Earnings per equity share (For respective periods) (In Rs.)						
	(1) Basic	1.98	1.46	1.72	3.44	2.83	6.10
	(2) Diluted	1.98	1.46	1.72	3.44	2.83	6.10

See accompanying notes to the financial results



**STATEMENT OF ASSETS AND LIABILITIES**

(Rs. in Lakhs)


PARTICULARS		As at 30th September, 2022	As at 31st March, 2022
		Unaudited	Audited
<b>I</b>	<b>ASSETS</b>		
<b>1</b>	<b>Non-current Assets</b>		
	(a) Property, Plant and equipment	5,626.63	6,018.33
	(b) Capital work-in-progress	-	10.00
	(c) Intangible Assets	15.64	18.25
	(d) Right of use assets	93.07	105.76
		5,735.34	6,152.34
	(e) Financial Assets		
	(i) Investments	2,651.75	2,121.25
	(ii) Other Financial Assets	463.31	463.51
	(f) Deferred Tax Assets (Net)	22.57	-
	(g) Income Tax Assets	160.59	111.63
	<b>Total Non-Current Assets</b>	<b>9,033.56</b>	<b>8,848.73</b>
<b>2</b>	<b>Current Assets</b>		
	(a) Inventories	5,721.69	7,992.33
	(b) Financial Assets		
	(i) Investments	4,743.64	2,146.89
	(ii) Trade receivables	12,760.82	13,570.83
	(iii) Cash and cash equivalents	974.39	379.58
	(iv) Other Bank balances	114.38	1,215.24
	(v) Loans and Advances	70.38	78.82
	(vi) Other financial assets	16.75	52.51
	(c) Other current assets	423.79	432.50
	<b>Total Current Assets</b>	<b>24,825.84</b>	<b>25,868.70</b>
	<b>TOTAL ASSETS</b>	<b>33,859.40</b>	<b>34,717.43</b>
<b>II</b>	<b>EQUITY AND LIABILITIES</b>		
<b>1</b>	<b>EQUITY</b>		
	(i) Equity Share Capital	2,505.60	2,505.60
	(ii) Other Equity	19,712.45	18,871.68
	<b>TOTAL EQUITY</b>	<b>22,218.05</b>	<b>21,377.28</b>
	<b>Liabilities</b>		
<b>2</b>	<b>NON-CURRENT LIABILITIES</b>		
	(a) Financial Liabilities		
	(i) Lease Liabilities	79.59	90.67
	(b) Provisions	151.09	154.09
	(c) Deferred Tax Liabilities(Net)	-	4.81
	<b>TOTAL NON-CURRENT LIABILITIES</b>	<b>230.68</b>	<b>249.57</b>
<b>3</b>	<b>CURRENT LIABILITIES</b>		
	(a) Financial Liabilities		
	(i) Borrowings	692.18	311.10
	(ii) Lease Liabilities	21.64	20.58
	(iii) Trade Payables:		
	Due to Micro and Small Enterprises	7.66	14.92
	Due to other than Micro and Small Enterprises	8,168.14	12,142.50
	(iv) Other financial liabilities	774.30	420.16
	(b) Other current liabilities	1,741.04	175.58
	(c) Provisions	5.71	5.74
	<b>TOTAL CURRENT LIABILITIES</b>	<b>11,410.67</b>	<b>13,090.58</b>
	<b>TOTAL EQUITY AND LIABILITIES</b>	<b>33,859.40</b>	<b>34,717.43</b>



**ANUH PHARMA LIMITED**  
**CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30th SEPTEMBER, 2022**

(Rs. in Lakhs)

Particulars	Half year ended 30th September, 2022		Half year ended 30th September, 2021	
	Unaudited		Unaudited	
<b>(A) CASH FLOW FROM OPERATING ACTIVITIES:</b>				
NET PROFIT BEFORE TAX		2,255.14		1,814.74
Adjustment for:				
Depreciation and Amortization	485.94		596.10	
Finance Costs	16.59		56.10	
Interest Income	(22.83)		(54.13)	
Market to Market (gain) / loss on investment	(176.33)		(169.09)	
Market to Market (gain) / loss on Derivative	-		(1.27)	
Provision for Gratuity & Leave Encashment	(11.46)		3.92	
Doubtful Debts Provision written back	-		(11.23)	
Dividend Income	(68.64)		(64.09)	
(Profit)/Loss on Sale of Property, Plant and Equipment	(1.07)		(2.83)	
(Profit)/Loss on Sale of Investment	(26.51)		(82.38)	
		195.69		271.10
<b>OPERATING PROFIT BEFORE WORKING CAPITAL CHANGES</b>		<b>2,450.83</b>		<b>2,085.84</b>
Adjustment for:				
Trade and Other Receivables	810.01		(1,354.56)	
Inventories	2,270.63		2,063.99	
Other Financial Assets	1,111.61		17.52	
Loans and Advances	8.44		33.98	
Other Current Assets	8.72		1,097.61	
Trade Payables	(3,981.62)		(3,642.23)	
Other Financial Liabilities	355.51		272.05	
Other current Liabilities	1,565.46		131.09	
Gratuity & Leave Encashment paid	(1.35)		(27.51)	
		2,147.41		(1,408.06)
<b>CASH GENERATED FROM OPERATIONS</b>		<b>4,598.24</b>		<b>677.78</b>
Direct Taxes paid	(603.96)	(603.96)	(387.76)	(387.76)
<b>NET CASH FROM OPERATIONS</b>		<b>3,994.29</b>		<b>290.02</b>
<b>(B) CASH FLOW FROM INVESTING ACTIVITIES:</b>				
(Purchase)/Sale of Investments [net]	(2,924.42)		(2,489.84)	
Purchase of Property, Plant and Equipment and Capital Work in Progress	(78.22)		(55.54)	
Sale of Property, Plant and Equipment	3.81		6.87	
Interest Income	48.13		38.82	
Dividend Income	68.64		64.09	
<b>NET CASH (USED IN) INVESTING ACTIVITIES</b>		<b>(2,882.06)</b>		<b>(2,435.60)</b>
<b>(C) CASH FLOW FROM FINANCING ACTIVITIES:</b>				
Total proceeds from Borrowings (net of repayments):				
Secured Loans/Short Term Borrowings	381.08		2,967.81	
Payment of Lease Liabilities	(15.39)		(2.57)	
Finance Costs	(5.18)		(51.85)	
Dividend paid (including tax thereon)	(877.93)		(752.32)	
<b>NET CASH (USED IN) / GENERATED FROM FINANCING ACTIVITIES</b>		<b>(517.42)</b>		<b>2,161.07</b>
<b>NET INCREASE / (DECREASE) IN CASH AND CASH EQUIVALENTS (A + B + C)</b>		<b>594.81</b>		<b>15.49</b>
CASH AND CASH EQUIVALENT AS AT THE BEGINNING OF THE PERIOD		379.58		219.84
CASH AND CASH EQUIVALENT AS AT THE END OF THE PERIOD		974.39		235.33



Notes:-

1. The results of the quarter and half year ended 30th September, 2022 were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 7th November, 2022. The statutory auditors of the Company carried out a "Limited Review" of the financial results for quarter and half year ended 30th September, 2022.

2. Other Financial indicators

(Rs. in Lakhs)

Particulars	3 months ended 30/09/2022	3 months ended 30/06/2022	3 months ended 30/09/2021	6 months ended 30/09/2022	6 months ended 30/09/2021	12 months ended 31/03/2022
EBITDA	1,543.71	1,213.96	1,438.78	2,757.68	2,466.93	5,204.26
% of EBITDA Margin	13.42	10.43	13.23	11.91	10.92	10.69
EBITDA (Adjusted to Forex (gain) / loss and Mark to Market (gain) / loss on Investment in Mutual funds)	1,451.15	1,277.80	1,318.51	2,728.95	2,368.10	5,241.59
% of Adjusted EBITDA Margin	12.61	10.98	12.13	11.79	10.48	10.77

3. The Company has identified Bulk drug and Chemicals as its only primary reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly, no-separate segment information has been provided.

4. Previous period's figures have been regrouped and reclassified, wherever necessary, to correspond with those of the current period.

For Anuh Pharma Ltd.



Ritesh Shah  
Joint Managing Director  
(DIN: 02496729)



For Anuh Pharma Ltd.



Vivek Shah  
Joint Managing Director  
(DIN: 02878724)

Place : Mumbai

Date : 7th November, 2022